Triple-negative breast cancer (TNBC) is immune-activated, suggesting that immunotherapy may be a viable treatment strategy. Immunotherapy was evaluated and approved in some TNBC clinical trials. But there is evidence for the potential benefits in subtype populations. A quantitative understanding of the complexity of the immune-cancer interactions is presently insufficient in the immune microenvironment. The metabolism of immune cells affects their differentiation and function, metabolic reprogramming may provide promising therapeutic targets for the treatment of TNBC.
This Research Topic aims to provide a clinical and basic overview of immunotherapy in TNBC, including immunotherapy biomarkers, immune checkpoint inhibitors, immunomodulatory antibodies, tumor-infiltrating lymphocytes, cytokines, metabolic changes, and clinical outcomes. We welcome studies on how genetic alterations affect the composition of immune cells present in the tumor microenvironment; studies that seek to uncover the physical mechanisms in tumor metabolic reprogramming and link these changes to targetable molecular mechanisms to generate new physical science-inspired clinical translational insights; as well as studies that will contribute to a basic understanding of the TNBC microenvironment, identification of potential biomarkers, and would aid in the design and interpretation of clinical trials.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Triple-negative breast cancer (TNBC) is immune-activated, suggesting that immunotherapy may be a viable treatment strategy. Immunotherapy was evaluated and approved in some TNBC clinical trials. But there is evidence for the potential benefits in subtype populations. A quantitative understanding of the complexity of the immune-cancer interactions is presently insufficient in the immune microenvironment. The metabolism of immune cells affects their differentiation and function, metabolic reprogramming may provide promising therapeutic targets for the treatment of TNBC.
This Research Topic aims to provide a clinical and basic overview of immunotherapy in TNBC, including immunotherapy biomarkers, immune checkpoint inhibitors, immunomodulatory antibodies, tumor-infiltrating lymphocytes, cytokines, metabolic changes, and clinical outcomes. We welcome studies on how genetic alterations affect the composition of immune cells present in the tumor microenvironment; studies that seek to uncover the physical mechanisms in tumor metabolic reprogramming and link these changes to targetable molecular mechanisms to generate new physical science-inspired clinical translational insights; as well as studies that will contribute to a basic understanding of the TNBC microenvironment, identification of potential biomarkers, and would aid in the design and interpretation of clinical trials.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
